ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.369,21
1,09%
S&P 500
5.186,95
0,12%
Dow Jones
38.913,46
0,16%
Euro vs US Dollar
1,07815
0,13%
Bitcoin
63.259,13
0,14%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Opiant Pharmaceuticals Inc (OPNT)

  7. Opiant Pharmaceuticals Inc (OPNT) News

OPNT

Opiant Pharmaceuticals (OPNT)

Opiant Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:OPNT
DatumZeitQuelleÜberschriftSymbolFirma
13/03/202311h16Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:OPNTOpiant Pharmaceuticals Inc
10/03/202312h05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/03/202320h02Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/03/202319h56Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/03/202319h17Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/03/202319h14Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/03/202319h10Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/03/202319h07Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/03/202319h02Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:OPNTOpiant Pharmaceuticals Inc
03/03/202315h27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
03/03/202315h25Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
03/03/202315h23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
03/03/202315h21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
03/03/202315h20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
03/03/202315h17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
03/03/202315h11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
03/03/202315h09Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
03/03/202315h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
03/03/202315h01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
03/03/202314h57Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
27/02/202322h05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OPNTOpiant Pharmaceuticals Inc
16/02/202323h14Edgar (US Regulatory)Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
07/02/202322h01GlobeNewswire Inc.Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLCNASDAQ:OPNTOpiant Pharmaceuticals Inc
06/02/202318h14Edgar (US Regulatory)Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/02/202314h00GlobeNewswire Inc.Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLCNASDAQ:OPNTOpiant Pharmaceuticals Inc
31/01/202322h23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
31/01/202322h22Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
31/01/202322h20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
19/01/202322h05GlobeNewswire Inc.Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid OverdoseNASDAQ:OPNTOpiant Pharmaceuticals Inc
09/01/202323h17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:OPNT

Kürzlich von Ihnen besucht

TG
DTE
Deutsche Telekom
DBI
TDXP
Tec DAX
FX
EURGBP
Euro vs Sterling
TG
TUI1
Tui
NYSE
KO
Coca Cola
NASDAQ
AAPL
Apple
AMEX
SPY
SPDR S&P 500
NASDAQ
GOOGL
Alphabet
TG
BAS
BASF
FX
EURUSD
Euro vs US Dollar
CCOM
US500
US 500
AMEX
XLV
Health Care Select Sector
DBI
DAX
DAX
NASDAQ
MSFT
Microsoft
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten